19, 2007, QIAGEN/Digene filed a motion for summary judgment seeking judgment against all of Third Wave's antitrust claims. This motion was granted in January 2008. The District Court dismissed the antitrust claims against QIAGEN/Digene, noting that Third Wave had "failed to show any violations." However, the District Court also dismissed QIAGEN/Digene's patent suit based on the court's construction of the patent claims -- constructions with which QIAGEN/Digene disagrees and is now appealing in the Federal Circuit.
About QIAGEN
QIAGEN N.V., a Netherlands holding company, is the leading provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing, and pharmaceutical process control. QIAGEN's assay technologies include what is considered to be the broadest panel of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,600 people in more than 30 locations worldwide. Further information about QIAGEN can be found at www.qiagen.com.
The QIAGEN N.V. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3692
SAFE HARBOR STATEMENT
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations due to the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
CONTACT: QIAGEN N.V. Dr. Solveigh Mahler, Director Investor Relations +49 2103 29 11710 solveigh.maehler@qiagen.com Investor Relations North America Albert F. Fleury +1 301 944 7028 albert.fleury@qiagen.com QIAGEN GmbH Dr. Thomas Theuringer, Associate Director Public Relations +49-2103-29-11826 thomas.theuringer@qiagen.com
